DelveInsight’s “Adeno-Associated Virus Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Adeno-Associated Virus, historical and forecasted epidemiology as well as the Adeno-Associated Virus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Adeno-Associated Virus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Adeno-Associated Virus Market Forecast
Some of the key facts of the Adeno-Associated Virus Market Report:
- The Adeno-Associated Virus market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- Haemophilia A, Haemophilia B, Choroideremia, Retinitis pigmentosa, Fabry disease, Pompe disease, Hunter syndrome, Parkinson's disease, Batten disease, Duchenne muscular dystrophy (DMD), and Spinal Muscular Atrophy (SMA) are the major indications for which the most clinical trials are currently being conducted
- There were 2,863,103 prevalent cases of specific indications for AAV gene therapies in the 7MM population in 2020
- Germany had the most instances of the disease among the EU-5 nations in 2020, with 441,670
- According to the 7MM, there were 43,243 and 10,811 prevalent cases of haemophilia A and haemophilia B correspondingly in the year 2020
- Key Adeno-Associated Virus Companies: BioMarin Pharmaceutical, Pfizer, uniQure, CSL Behring, NightstaRx Ltd, MeiraGTx, Neurocrine Biosciences, Voyager Therapeutics, Roche, Sangamo Therapeutics, Freeline Therapeutics, Spark Therapeutics, Asklepios Biopharmaceutical, Audentes Therapeutics, Sarepta Therapeutics, Horama S.A., MeiraGTx UK II Ltd, RegenxBio, Amicus Therapeutics, and others
- Key Adeno-Associated Virus Therapies: Valoctocogene Roxaparvovec (BMN 270), PF-06939926, Fidanacogene elaparvovec, AMT-061, Timrepigene emparvovec (BIIB111), Giroctocogene fitelparvovec (SB-525), BIIB112 (AAV8-RPGR), NLX P101 (AAV-GAD), VY-AADC (NBIb-1817/ AAV2-hAADC), SPK-8011, ST-920, FLT190, SPK-3006 (AAV-sec-GAA), ACTUS-101, AT845, SRP-9001, HORA-PDE6B, AAV-RPGR (AAV2/5-RPGR), RGX-121, SB-913, AT-GTX-501 (scAAV9.CB.CLN6), AT-GTX-502 (scAAV9.P546.CLN3), and others
- The Adeno-Associated Virus market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Adeno-Associated Virus pipeline products will significantly revolutionize the Adeno-Associated Virus market dynamics.
Adeno-Associated Virus Overview
For a variety of illnesses (including hereditary abnormalities, some cancers, and specific viral infections), gene therapy is a viable treatment option. In gene therapy, "vectors" are used, and these might be viral or non-viral vectors.
Get a Free sample for the Adeno-Associated Virus Market Report
https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market
Adeno-Associated Virus Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Adeno-Associated Virus Epidemiology Segmentation:
The Adeno-Associated Virus market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Adeno-Associated Virus
- Prevalent Cases of Adeno-Associated Virus by severity
- Gender-specific Prevalence of Adeno-Associated Virus
- Diagnosed Cases of Episodic and Chronic Adeno-Associated Virus
Download the report to understand which factors are driving Adeno-Associated Virus epidemiology trends @ Adeno-Associated Virus Epidemiology Forecast
Adeno-Associated Virus Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Adeno-Associated Virus market or expected to get launched during the study period. The analysis covers Adeno-Associated Virus market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Adeno-Associated Virus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Adeno-Associated Virus Therapies and Key Companies
- Valoctocogene Roxaparvovec (BMN 270): BioMarin Pharmaceutical: Phase III
- PF-06939926: Pfizer: Phase III
- Fidanacogene elaparvovec: Pfizer (initiated by Spark Therapeutics): Phase III
- AMT-061: uniQure/CSL Behring: Phase III
- Timrepigene emparvovec (BIIB111): NightstaRx Ltd, a Biogen Company
- Giroctocogene fitelparvovec (SB-525): Pfizer (previously Sangamo Biosciences)
- BIIB112 (AAV8-RPGR): NightstaRx Ltd, a Biogen Company
- NLX P101 (AAV-GAD): MeiraGTx
- VY-AADC (NBIb-1817/ AAV2-hAADC): Neurocrine Biosciences/ Voyager Therapeutics
- SPK-8011: Roche (previously Spark Therapeutics)/Pfizer
- ST-920: Sangamo Therapeutics
- FLT190: Freeline Therapeutics
- SPK-3006 (AAV-sec-GAA): Spark Therapeutics
- ACTUS-101: Asklepios Biopharmaceutical (Actus Therapeutics)
- AT845: Audentes Therapeutics
- SRP-9001: Roche/Sarepta Therapeutics
- HORA-PDE6B: Horama S.A.
- AAV-RPGR (AAV2/5-RPGR): MeiraGTx UK II Ltd
- RGX-121: RegenxBio
- SB-913: Sangamo Therapeutics
- AT-GTX-501 (scAAV9.CB.CLN6): Amicus Therapeutics
- AT-GTX-502 (scAAV9.P546.CLN3): Amicus Therapeutics
Discover more about therapies set to grab major Adeno-Associated Virus market share @ Adeno-Associated Virus Treatment Market
Adeno-Associated Virus Market Drivers
- Ability to treat a broad array of conditions
- AAV Capsid Selection and Optimization
- Longer Transgene Expression
Adeno-Associated Virus Market Barriers
- Shortcomings of AAV based Gene Therapies
- Failures and risks associated with clinical trials
Scope of the Adeno-Associated Virus Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Adeno-Associated Virus Companies: BioMarin Pharmaceutical, Pfizer, uniQure, CSL Behring, NightstaRx Ltd, MeiraGTx, Neurocrine Biosciences, Voyager Therapeutics, Roche, Sangamo Therapeutics, Freeline Therapeutics, Spark Therapeutics, Asklepios Biopharmaceutical, Audentes Therapeutics, Sarepta Therapeutics, Horama S.A., MeiraGTx UK II Ltd, RegenxBio, Amicus Therapeutics, and others
- Key Adeno-Associated Virus Therapies: Valoctocogene Roxaparvovec (BMN 270), PF-06939926, Fidanacogene elaparvovec, AMT-061, Timrepigene emparvovec (BIIB111), Giroctocogene fitelparvovec (SB-525), BIIB112 (AAV8-RPGR), NLX P101 (AAV-GAD), VY-AADC (NBIb-1817/ AAV2-hAADC), SPK-8011, ST-920, FLT190, SPK-3006 (AAV-sec-GAA), ACTUS-101, AT845, SRP-9001, HORA-PDE6B, AAV-RPGR (AAV2/5-RPGR), RGX-121, SB-913, AT-GTX-501 (scAAV9.CB.CLN6), AT-GTX-502 (scAAV9.P546.CLN3), and others
- Adeno-Associated Virus Therapeutic Assessment: Adeno-Associated Virus current marketed and Adeno-Associated Virus emerging therapies
- Adeno-Associated Virus Market Dynamics: Adeno-Associated Virus market drivers and Adeno-Associated Virus market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Adeno-Associated Virus Unmet Needs, KOL’s views, Analyst’s views, Adeno-Associated Virus Market Access and Reimbursement
To know more about Adeno-Associated Virus companies working in the treatment market, visit @ Adeno-Associated Virus Clinical Trials and Therapeutic Assessment
Table of Contents
1. Adeno-Associated Virus Market Report Introduction
2. Executive Summary for Adeno-Associated Virus
3. SWOT analysis of Adeno-Associated Virus
4. Adeno-Associated Virus Patient Share (%) Overview at a Glance
5. Adeno-Associated Virus Market Overview at a Glance
6. Adeno-Associated Virus Disease Background and Overview
7. Adeno-Associated Virus Epidemiology and Patient Population
8. Country-Specific Patient Population of Adeno-Associated Virus
9. Adeno-Associated Virus Current Treatment and Medical Practices
10. Adeno-Associated Virus Unmet Needs
11. Adeno-Associated Virus Emerging Therapies
12. Adeno-Associated Virus Market Outlook
13. Country-Wise Adeno-Associated Virus Market Analysis (2019–2032)
14. Adeno-Associated Virus Market Access and Reimbursement of Therapies
15. Adeno-Associated Virus Market Drivers
16. Adeno-Associated Virus Market Barriers
17. Adeno-Associated Virus Appendix
18. Adeno-Associated Virus Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
